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AbstrAct
background Thyrotoxicosis is both rarer and more 
severe in children than in adults, rendering management 
difficult and often unsatisfactory.
Objective To ascertain outcome in a geographically 
defined area of Scotland between 1989 and 2014.
Method Retrospective case note review with follow-up 
questionnaire to family doctors for patients with Graves’ 
disease and Hashimoto’s thyroiditis.
results Sixty-six patients (58 females:8 males) 
comprising 53 with Graves’ disease and 13 with 
Hashimoto’s thyroiditis were diagnosed at median 10.4 
(2.9–15.8) years and followed up for 11.8 (2.6–30.2) 
years. Antithyroid drug (ATD) therapy was stopped 
electively in 35 patients after 4.5 (1.5–8.6) years, 
resulting in remission in 10/13 Hashimoto’s thyroiditis 
and 10/22 Graves’ disease. Side effects occurred in 12 
patients receiving carbimazole, six of whom changed to 
propylthiouracil; no adverse events occurred in the latter 
patients. Second-line therapy was given to 37 patients 
(34 with Graves’ disease), comprising radioiodine (22) 
at 15.6 (9.3–24.4) years for relapse (6), poor control/
adherence (14) or electively (2); and surgery (16) at 12 
(6.4–21.3) years for relapse (4), poor control/adherence 
(5) and electively (7). Adherence problems with thyroxine 
replacement were reported in 10/33 patients in 
adulthood.
conclusions Hashimoto’s thyroiditis should be 
distinguished from Graves’ disease at diagnosis since 
the prognosis for remission is better. Remission rates 
for Graves’ disease are low (10/53 patients), time to 
remission variable and adherence with both ATD and 
thyroxine replacement often problematic. We recommend 
(a) the giving of long-term ATD rather than a fixed course 
of treatment in GD and (b) meticulous and realistic 
counselling of families from the time of diagnosis 
onwards. 
IntrOductIOn
Child and adolescent thyrotoxicosis is both less 
common and more severe than in adults.1 As a 
result, its management is controversial and often 
unsatisfactory.2–4 Treatment guidelines have been 
published in Japan, but these relate exclusively to 
Graves’ disease.5 
A 12–18-month course of antithyroid drug (ATD) 
has been reported to result in remission in roughly 
50% of patients.6 In adult practice, it is common 
to treat with ATD for this period before checking 
to see if remission has occurred.7 8 However, 
prolonged low-dose ATD administration has been 
shown to prevent relapse of Graves’ disease in 
adults >35 years of age.9
The American Thyroid Association acknowledges 
that the treatment of children with Graves’ disease 
varies considerably but states that medical therapy 
for 1 year is ‘still considered first line treatment for 
most children’.10 By contrast, Lippe et al quote a 
25% per 2-year remission rate in paediatric Graves’ 
disease and support the approach of awaiting remis-
sion rather than stopping treatment at a defined 
time period in order to assess disease status.11 
More recently a study of 154 French children with 
Graves’ disease showed a cumulative remission rate 
of 20% after 4 years, rising to 49% after 10 years.12 
What this study adds?
 ► Thyrotoxicosis caused by the hyperthyroid 
phase of Hashimoto’s thyroiditis must be 
carefully distinguished from Graves’ disease 
since the former carries a better prognosis for 
spontaneous remission.
 ► Time taken for Graves’ disease to remit is too 
variable for a standard interval (eg, 2–3 years) 
for stopping antithyroid treatment to be set.
 ► Adherence difficulties are common not only 
before but also after second-line treatment 
when long-term thyroxine replacement is 
required. This has implications for management, 
including the initial education and counselling 
of families.
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What is already known on this topic?
 ► Thyrotoxicosis is rarer and more severe in 
children and adolescents than in adults, with 
lower remission rates after antithyroid drug 
treatment.
 ► Management of paediatric thyrotoxicosis 
is controversial, particularly concerning the 
length of time that antithyroid drugs should be 
administered.
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Rivkees has highlighted the potential hazards of ATD therapy, 
particularly with propylthiouracil (PTU).4
In 2005, the British Society for Paediatric Endocrinology 
and Diabetes (BSPED) launched a study examining outcome of 
thyrotoxicosis in patients treated with either dose titration (DT) 
or the block and replace (BR) regime, stopping therapy at 3 years 
to assess remission status.13 The purpose of our study was to 
examine the outcomes of an unselected Scottish population of 
children and adolescents with thyrotoxicosis in relation to aeti-
ology, duration of treatment, achievement of spontaneous remis-
sion and adherence both with short-term ATD and long-term 
thyroxine replacement.
Patients and methods
The case notes of patients diagnosed with thyrotoxicosis under 
the age of 16 years in Greater Glasgow, Ayrshire & Arran, 
Argyll and Clyde and Lanarkshire between 1989 and 2012 were 
reviewed. Clinical and biochemical features and outcome in 
relation to treatment were documented. In April 2015, a ques-
tionnaire was sent to the patients’ family doctors requesting 
information on current thyroid status, treatment with ATD 
or thyroxine replacement, adherence with medication and the 
development of additional disorders.
Biochemical parameters studied included free thyroxine 
(fT4) and total T4 (TT4), the former largely replacing the 
latter by 2000; total tri-iodothyronine (T3); thyroid-stimu-
lating hormone (TSH); antimicrosomal and thyroid perox-
idase (TPO) antibodies, the latter replacing the former in 
1999. Assays for these hormones and antibodies were carried 
out using commercial kits. TSH receptor antibody (TRAB) 
was initially measured as percentage displacement of TSH 
binding using an in-house assay as described by Wilson et 
al.14 From 1999, this assay was replaced by THYBIA TSH-re-
ceptor antibody RIA kit manufactured by Diasorin. Intra-
assay and inter-assay coefficients of variation were <6% and 
<14%, respectively, at 20 and 45 U/L.
Thyrotoxicosis was defined as elevated thyroid hormones: 
free T4 >30 pmol/L or TT4 >160 nmol/L, T3 >3 nmol/L with 
TSH <0.1 mU/L, in a patient with clinical symptoms of thyro-
toxicosis (eg, heat intolerance, increased sweating, palpitations 
and weight loss).
Specific criteria were set to distinguish between Graves’ 
disease and Hashimoto’s thyroiditis. Graves’ disease was 
defined as thyrotoxicosis with either eye signs or elevated TSH 
receptor antibodies (either ≥10% displacement of TSH binding 
or ≥10 U/L) with or without positive thyroid autoantibodies 
or both. Hashimoto’s disease was defined as thyrotoxicosis, 
usually with positive antithyroid antibodies—antimicrosomal 
antibody titre >1/400, anti-TPO antibodies>30 mU/L; in the 
absence of both eye signs and elevated TSH receptor antibodies. 
Presence of antithyroid antibodies was not a prerequisite for 
the diagnosis of Hashimoto’s disease since organ-restricted 
disease may occur.15 Patients with neonatal thyrotoxicosis and 
hyperthyroidism associated with dysmorphic syndromes were 
excluded.
Thyroid size, assessed clinically and supplemented where 
available by ultrasound measurements and clinical photographs, 
was graded as normal, and small, moderate or large goitre. 
Thyroid ophthalmopathy was defined clinically as absent; mild 
when the patient had some lid retraction and was considered 
by the family to have developed slight prominence of the eyes; 
moderate when there was clinically obvious orbital projection—
exophthalmos; and severe when eye prominence was so obvious 
as to be unsightly, with or without oedema and injection of the 
conjunctivae.
ATD treatment was recorded according to type—carbimazole 
or PTU; mode—ATD alone (DT) or ATD with thyroxine (BR). 
Duration, side effects, adherence and date/age of stopping treat-
ment were also recorded.
Remission was defined as no recurrence of thyrotoxicosis 
during the study period (end of July 2015) following cessation 
of ATD and relapse as recurrence of thyrotoxicosis at any time 
off treatment.
Continuous variables were described as median and ranges, 
and intergroup comparison was performed using Mann–Whitney 
U tests. χ2 test was used for categorical variables. P < 0.05 was 
considered to be statistically significant, and all analyses were 
performed using Minitab V.17.
results
Between 1989 and 2012 inclusive, 77 patients with thyrotoxi-
cosis were seen, of whom 11 were ineligible for the following 
reasons: Down (4) and DiGeorge syndrome (1), neonatal 
Graves’ disease (4), Hashimoto’s encephalopathy with incip-
ient untreated hyperthyroidism (1) and case sheet unavailable 
(1). Three of the eligible 66 patients shown in table 1 were 
of Indian, Pakistani and Ghanaian origin, the remainder were 
Caucasian. Two patients were referred to ophthalmology with 
severe proptosis, both of whom were managed conservatively.
Median (range) age at diagnosis and age on 1 January 2016 was 
11.8 (2.8–16.9) and 25 (13.7–39.7). Excluding three patients 
lost to follow-up at 1.3, 2.4 and 4 years median (range) dura-
tion of follow-up was 11.8 (2.6–30.2) years. In total, 53 patients 
(45 girls: 8 boys) satisfied the criteria for Graves’ disease, and 
13 patients (all girls) had Hashimoto’s disease. Patients with 
Hashimoto’s thyroiditis were older (P=0.01) with lower free T4 
(P =0.02) than those with Graves’ disease.
Associated disorders in Graves’ disease comprised diabetes 
mellitus which had developed after diagnosis in four girls and 
pauciarticular juvenile idiopathic arthritis developing before 
diagnosis in one. Two patients with Hashimoto’s disease devel-
oped systemic lupus erythematosus and mild Behçet’s syndrome 
in adulthood.
Completed questionnaires were received from 43 (66%) 
family doctors. Eleven patients had changed their thyroid status 
with development of diabetes mellitus (one), relapse of Graves’ 
disease (three) and development of hypothyroidism (six). Of the 
23 patients in whom questionnaires were not received, 10 were 
known to be on thyroxine replacement following radioiodine (5) 
or surgery (5) while thyroid and treatment status was known in 
a further 4 patients up to the end of 2014 leaving 9 patients in 
whom thyroid status could not be confirmed. Also, 5 of the 48 
patients had had nine children, including a twin pregnancy in 
which one baby was stillborn.
Outcome with Atd therapy 
See table 2 and figure 1.
All patients received carbimazole initially using DT 
in 46 and BR in 20. Apart from the seven patients who 
were enrolled into the BSPED trial, there was no standard 
protocol for stopping ATD during the study period. Three 
patients were lost to follow-up after 4, 2.4 and 1.3 years. 
Adverse events associated with ATD were seen in 12 patients 
receiving carbimazole comprising rash (n=5), neutropenia 
(n=2) and sore throat (n=4). Six patients were switched to 
PTU with no reported side effects. One patient with Graves’ 
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table 1 Clinical and biochemical features at diagnosis of 66 patients with thyrotoxicosis in the west of Scotland seen between 1989 and 2012 
with a diagnosis of Graves’ disease or Hashimoto’s thyroiditis
Graves’ disease Hashimoto’s thyroiditis P value
Number
(F:M)
53
F:45/M:8
13
F:13/M:0
Mean/median (range) age at time of diagnosis 9.9/10.3
(1.8–15.8)
12.3/13.4
(6–15.6)
0.02
Dose titration/block and replace 34/19 12/1
TRAB+ve, eye signs +ve
TRAB+ve, eye signs –ve
TRAB+ve, eye signs N/A
TRAB –ve/N/A, eye signs+ve
n=24
n=16
n=4
n=4/5
Not applicable
Eye signs None (n=6)
Lid lag/mild prominence (n=10)
Definite exophthalmos (n=25)
Marked exophthalmos (n=6)
N/A (6)
Not applicable
Goitre None (5)
Small (n=17)
Moderate (n=20)
Large (n=4)
Not specified (n=7)
None (n=3)
Small (n=4)
Moderate (n=2)
Large (n=0)
Not specified (n=4)
0.18
First-degree relative with thyroid disease, for example, mother
Second-degree relative affected, for example, aunt (n=30)
First degree (n=7)
Second degree (n=15)
First+second degree (n=3)
First degree (n=2)
Second degree (n=2)
First+second degree (n=1)
Median (range) fT4 (pmol/L)
(n=55)
(reference range 10–23)
62 (6.2–154.0)
(n=42)
40.4 (4.8–78.4)
(n=13)
0.01
Median (range) TT4 (nmol/L)
(n=55)
(reference range 80–160)
324
(45–1117)
(n=42)
293
(35–569)
(n=13)
0.09
Median (range) TT3 (nmol/L)
(n=48)
(reference range 1.6–3.0)
8.9 (2.2–22.9)
(n=36)
4.8 (3.1–8.9)
(n=12)
0.30
Median (range) TRAB (U/L) (n=37)
(reference range<10)
36 (<3–94)
(n=26)
<3 (<3–9)
(n=13)
Median (range) TRAB (%)
(n=15)
(reference range<10% displacement of TSH binding)
46 (20–68)
(n=15)
N/A
Median (range) TPO (mU/L) (n=43)
(reference range<30)
419 (7–7643)
(n=30)
153 (10 to >2000)
(n=13)
Median (range) antimicrosomal titre (n=15)
(reference range<1/400)
1/1600 (<1/400–1/256 000)
(n=15)
N/A
(n=0)
Where the data for a given row are fewer than the total patient number (66), the available number is given as (n=) in the left-hand column. 
F, female; fT3, free tri-iodothyronine; fT4, free thyroxine; M, male; N/A, not available; N/K, not known; TPO, thyroid peroxidase; TRAB, TSH receptor antibody; TT3, total T3; TT4, 
total T4. 
disease remained on ATD throughout the study period from 
2.9 to 22 years.
Thirty-five patients (23 Graves’s; 12 Hashimoto’s) stopped 
ATD for possible remission, and their data are shown in table 2. 
Also, 12 had been treated for <3 (range 0.65–2.96) years and 23 
for ≥3 (range 3.7–14.7) years.
Also, 20 patients (10 Graves’; 10 Hashimoto’s) remitted after 
4.2 (0.5–8.9) years (n=17, duration unknown in 3), while 15 
(13 Graves’; 2 Hashimoto’s) relapsed. Cause of thyrotoxicosis 
and total (but not free) T4 at presentation were the only signifi-
cant differences between the two groups.
Outcome with second-line treatment
See figure 1.
Twenty-seven patients stopped ATD to receive second-line 
treatment; for poor disease control in 19 (associated with known 
adherence difficulties in 11) and pending elective treatment in 8.
surgical treatment
Sixteen patients underwent thyroidectomy, the type being at the 
discretion of the surgeon responsible. Subtotal thyroidectomy 
was performed in 12 patients between 1992 and 2003 at 12 
(6.4–20.2) years with recurrence in 2, remission in 2 and hypo-
thyroidism in 8. Total thyroidectomy was performed in four 
patients between 2006 and 2014 at 12.9, 18.7, 20.1 and 21.3 
years with hypothyroidism in all, and permanent hypoparathy-
roidism in the youngest patient. Keloid formation was seen in 
two patients.
radioiodine treatment
Twenty-two patients received radioiodine in the dose of 450 
(250–500) MBq at 15.6 (9.3–24.4) years. All but two became 
hypothyroid, mostly within 6 months of therapy. One patient 
with Graves’ disease required a second dose while two remained 
hyperthyroid, one diagnosed at 5.5 years and treated at 10.3 
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table 2 Clinical and biochemical features relating to outcome in 35 of 66 patients with thyrotoxicosis, diagnosed in the west of Scotland 
between 1989 and 2012 who stopped antithyroid drug (ATD) treatment for possible remission prior to treatment with either surgery or radioiodine 
therapy
remission after stopping Atd relapse after stopping Atd P value
Number (F:M) 20 (18F:2M) 15 (13F:2M)
Age at diagnosis, median (range) 12.2 (3.7–15.6)
(n=20)
9.3 (4.3–15.8)
(n=15)
0.29
Graves’s disease: Hashimoto’s thyroiditis 10:10 12:3 0.06
Goitre at diagnosis None (n=5)
Small (n=7)
Moderate (n=3)
Large (n=1)
Not specified (n=4)
Small (n=8)
Moderate (n=4)
Not specified (n=3)
-
Type of initial ATD treatment
 ► DT
 ► BR
DT: 13
BR:7
DT: 9
BR: 6
Median (range) fT4 (pmol/L) at diagnosis (n=34) 44.0 (4.8–105.0)
(n=19)
44.7 (27.8–124.1)
(n=15)
0.27
Median (range) TT4 (nmol/L) at diagnosis (n=34) 293
(35-733)
(n=19)
236 (19–733)
(n=15)
<0.01
Mean/median (range) TRAB (U/L) at diagnosis (n=25) 15/4 [<3–59)
(n=15)
22, 16 [<3–67)
(n=10)
0.30
Where the data for a given row are fewer than the total patient number (35), the available number is given as (n=) in the left-hand column.
BR, block and replace; DT, dose titration; fT4, free thyroxine; TRAB, TSH receptor antibody; TT4, total T4.
Figure 1 Flow diagram showing outcome in 77 children and adolescents with thyrotoxicosis seen in the west of Scotland 1989-2012. ATD, 
antithyroid drugs; GD,  Graves’ disease; HT, Hashimoto’s thyroiditis; RI, radioiodine therapy. 
years for poor control who subsequently received BR therapy; 
the other diagnosed at 9.2 years and treated at 18.5 years and 
who remained off treatment with mild thyrotoxicosis.
long-term follow-up
By the end of the study period, 33 of the 66 patients were known 
to be on thyroxine replacement. For these patients, adherence 
with treatment was not stated in 14, reported as reasonable or 
good in 9 and as poor in 10 with most recent TSH >20 mU/L 
in 3.
dIscussIOn
This study of patients with paediatric thyrotoxicosis in the 
west of Scotland over a 25-year period has enabled long-term 
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outcome to be assessed. It is of note that no serious side effects 
occurred during the 26 years of this regional study including 
none with PTU, although this medication should be avoided 
where possible in children.4 6
Inevitably, a study such as ours is limited by its retrospective 
nature and in particular the lack of a standard protocol, particu-
larly concerning duration of treatment with ATD. Moreover, assess-
ment of ophthalmopathy and thyroid enlargement was subjective. 
The relatively high prevalence (46/53) of eye signs in children with 
Graves’ disease compared with some studies16 may be explained by 
inclusion of mild signs such as lid lag rather than true proptosis. 
Of note, no patient developed eye disease of sufficient severity for 
steroid therapy or surgery to be contemplated.
This study highlights the importance of distinguishing between 
Hashimoto’s thyroiditis and Graves’ disease at presentation of 
hyperthyroidism. Many studies have focused on Graves’ disease 
alone as the cause of hyperthyroidism1–8 11 with some not 
mentioning Hashimoto’s disease in the differential diagnosis.6 8 
The American Thyroid Association guidelines describe ‘painless 
thyroiditis caused by lymphocytic inflammation’ and refer to its 
variable prevalence from 0.5% to 22% in different studies.10 An 
absolute distinction between the two disorders may be difficult; 
indeed some workers consider them to be at different ends of a 
continuum.17 However, the criteria applied in this study have 
proved clinically useful. Thus of 13 (19.6%) patients classified 
as Hashimoto’s thyroiditis in our study, 10 remitted sponta-
neously in contrast with only 10 documented remissions in the 
56 patients with Graves’ disease.
Since differentiation between Hashimoto’s thyroiditis and 
Graves’ disease requires thyroid receptor antibody measure-
ment, the results of which will be received some time after the 
initial thyroid function tests, it is the clinician’s responsibility to 
ensure that these results are pursued so that the family can be 
counselled appropriately.
The question of duration of ATD is contentious. It has been 
argued that there is no evidence from randomised trials that 
prolonging medical treatment increases the chance of remission in 
Graves’ disease.18 However, the disease has a natural history of 
remission in some cases, one study showing spontaneous remission 
in 8 of 26 patients treated with propranolol alone.19 Léger et al 
showed evidence for cumulative increase in remission rates in chil-
dren given repeated 2-year courses of treatment.11 A more recent 
study from Japan has reinforced this finding, with remission in 
334/639 (46.2%) of children and adolescents (median age 16 years) 
with Graves’ disease, and an increasing prevalence of remission 
with the duration of ATD treatment.20 Moreover, restoring euthy-
roidism in itself minimises thyroid autoimmunity and increases 
the chance of remission.21 22 In our study, the number of patients 
with Graves’ disease achieving spontaneous remission was insuffi-
cient and the patient population was not treated in systematic and 
defined courses to allow calculation of a cumulative incidence of 
remission. However, our data do not support the implementation 
of a set cut-off time, for example, 3 years, for assessing remission 
off therapy. Rather, they are consistent with Léger’s recommenda-
tion that ‘continuous treatment, rather than treatment cycles of 2 
years should be considered in future clinical trials’.’12
This study did not attempt to address the question of ATD 
regime—BR versus DT. The current evidence in adults favours 
DT since BR involves a higher ATD dose and hence a higher 
prevalence of adverse effects, with no proven benefit in terms 
of achieving remission.23 However, BR has the advantage of 
requiring less frequent monitoring and more consistent main-
tenance of euthyroidism than DT.24 The outcome of the BSPED 
prospective study should help to clarify this controversy.
A major problem encountered in this study is that of adher-
ence both with ATD treatment and thyroxine replacement. Poor 
adherence with ATD was documented in at least 11 of the 27 
patients receiving second-line treatment and might have been 
a factor in others with poor disease control. In adulthood, 10 
of the 33 patients known to be on long-term medication with 
thyroxine were reported by their family doctors as having 
problems—a serious matter for women of childbearing age.25 
Thus there is a risk that adherence problems with ATD may be 
exchanged for problems with long-term thyroxine replacement 
with ablative second-line treatment. Of note, the only patients 
receiving second-line therapy in this study to achieve remission 
were 2 of the 12 undergoing subtotal thyroidectomy. Although 
total rather than subtotal thyroidectomy is favoured in adult 
patients26 partly because of relatively high recurrence rates of 
5.3% and 7.9% with the latter,27 28 this option might be consid-
ered for patients with a particularly poor track record of adher-
ence to ATD treatment.
In conclusion, we advocate precise diagnosis followed by 
careful and realistic counselling in paediatric thyrotoxicosis. 
Families should be warned that ATD treatment may be required 
for many years in Graves’ disease; that the number of years 
of ATD treatment cannot be predicted and that if second-line 
treatment such as radioiodine and surgery is given lifelong treat-
ment with thyroxine is almost always needed. Reduction in ATD 
dosage should be cautious and slow before testing for remission.6 
With uncontrolled Graves’ disease, early recourse to second-line 
treatment will avoid years of educational disruption but adher-
ence may remain a problem. The culture of daily tablet-taking 
at the same time of day should be encouraged, and we would 
reinforce the need for continuing education of the patient and 
family in clinic.12
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